Skip to content
Inciteful Med

The Symptoms and Biology of ARSACS

Published: | Updated:

ARSACS is a genetic disorder caused by SACS gene mutations, resulting in a lack of the sacsin protein. This causes a classic triad of symptoms: cerebellar ataxia (unsteady movement), spasticity (muscle stiffness), and neuropathy (nerve damage). It may also affect emotions and thinking.

Key Takeaways

  • • ARSACS is characterized by a classic triad of symptoms: cerebellar ataxia, spasticity, and sensorimotor neuropathy.
  • • The condition is caused by inheriting two mutated copies of the SACS gene, resulting in a lack of functional sacsin protein.
  • • The loss of sacsin leads to cellular dysfunction, particularly damaging the Purkinje cells in the cerebellum that coordinate movement.
  • • In addition to physical symptoms, some individuals with ARSACS experience cognitive and emotional challenges known as Cerebellar Cognitive Affective Syndrome (CCAS).
  • • While symptoms usually emerge in early childhood, atypical presentations can include adult-onset symptoms, seizures, or tremors.

Understanding the science behind a diagnosis like ARSACS can help you feel more in control of the journey ahead. While the condition is complex, the physical symptoms and the biology causing them are closely linked. By looking “under the hood” at the cellular level, we can better understand why the body behaves the way it does.

The Classic Clinical Triad

Most people with ARSACS experience three core types of symptoms, often called the “classic triad.” These usually emerge in early childhood, often when a child is first learning to walk [1][2].

  1. Cerebellar Ataxia: This is a lack of muscle coordination caused by changes in the cerebellum, the part of the brain that controls balance and fine motor skills [1][3]. It often looks like a “drunken” or unsteady walk and can affect hand coordination and speech [3][4].
  2. Spasticity: This refers to muscle stiffness or involuntary muscle contractions [5]. In ARSACS, this primarily affects the legs, making them feel tight and sometimes difficult to move fluidly [6].
  3. Sensorimotor Neuropathy: This is damage to the peripheral nerves (the nerves that connect your brain and spinal cord to the rest of your body) [1]. It can cause muscle weakness (motor) and numbness or tingling (sensory) in the hands and feet [7][8].

The Biology: What is Happening Inside?

ARSACS is a recessive disorder, meaning a person must inherit two changed copies of the SACS gene (one from each parent) to develop the condition [9]. This is known as a biallelic mutation.

The Role of Sacsin

The SACS gene is responsible for producing a large, hardworking protein called sacsin [10]. In a healthy cell, sacsin acts like a “molecular chaperone”—it helps other proteins fold correctly and ensures the cell’s internal structure stays organized [11][12]. In ARSACS, these mutations cause the body to have almost no functional sacsin protein [9].

Cellular “Traffic Jams” and Power Failures

Without sacsin, two major problems occur inside the cells:

  • Cytoskeletal Bundling: Think of the cytoskeleton as the scaffolding of a cell. Without sacsin, a protein called vimentin begins to clump together into dense “bundles” [11][13]. This disrupts the cell’s internal transport system, like a traffic jam blocking an intersection.
  • Mitochondrial Dysfunction: Mitochondria are the “power plants” of the cell. Sacsin helps manage the constant splitting and merging (fission and fusion) of these power plants to keep them healthy [12][14]. Without it, the mitochondria become less efficient, leaving the cell without the energy it needs to thrive [15].

The Vulnerability of Purkinje Cells

While these cellular problems happen in many places, a specific type of cell in the brain is especially vulnerable: the Purkinje cell [15]. These are large, beautiful neurons in the cerebellum that serve as the main “command center” for coordinating movement [16]. Because they are so large and active, they are very sensitive to the “traffic jams” and energy shortages caused by the loss of sacsin. Eventually, these cells may stop working or die off, which leads to the balance and coordination issues seen in ARSACS [12][15].

Beyond the Triad: Cognitive and Atypical Features

While the physical triad is most common, we now know that ARSACS can affect more than just movement.

  • Cerebellar Cognitive Affective Syndrome (CCAS): The cerebellum also helps regulate emotions and “executive functions” (like planning and organizing) [17]. Some patients may experience challenges with word-finding, abstract reasoning, or emotional regulation [17][18].
  • Atypical Presentations: Because there are so many different mutations worldwide, some people don’t fit the “classic” mold. Some may have adult-onset symptoms, while others might experience seizures or movement disorders like tremors or rigidity [19][20][21]. Knowing these possibilities helps you and your doctor tailor a care plan that fits your specific needs.

If you want to know how doctors test for these specific hallmarks, read about Diagnosing ARSACS.

Frequently Asked Questions

What are the first signs and symptoms of ARSACS?
The first signs of ARSACS typically emerge in early childhood, often when a child is learning to walk. These include uncoordinated movement, muscle stiffness in the legs, and nerve damage that can cause weakness or numbness.
What causes ARSACS?
ARSACS is caused by inheriting two mutated copies of the SACS gene, one from each parent. This genetic change prevents the body from producing enough functional sacsin protein, which cells need to stay organized and generate energy.
How does the loss of the sacsin protein affect the body?
Without sacsin, cells experience internal protein 'traffic jams' and reduced energy from malfunctioning mitochondria. This damage is especially harmful to Purkinje cells in the cerebellum, which act as the brain's command center for coordinating movement.
Can ARSACS affect my emotions or cognitive function?
Yes, ARSACS can cause Cerebellar Cognitive Affective Syndrome (CCAS). This means some patients may experience difficulty with executive functions like planning and organizing, word-finding, or emotional regulation.
Why do my legs feel stiff with ARSACS?
Muscle stiffness, known as spasticity, is a core symptom of ARSACS. It primarily affects the legs, making them feel tight and sometimes difficult to move fluidly, especially after periods of rest.

Questions for Your Doctor

  • • How does the loss of sacsin protein specifically manifest in the physical symptoms we are seeing right now?
  • • Given the risk of mitochondrial dysfunction, are there specific metabolic or energy-supporting strategies we should consider?
  • • Can we assess for Cerebellar Cognitive Affective Syndrome (CCAS) to see if some of the emotional or school-related struggles are linked to the disease?
  • • Is the sensorimotor neuropathy in this case primarily axonal or demyelinating, and how does that affect the long-term plan for physical therapy?
  • • Are there any atypical features in this genetic presentation that might change our expectations for disease progression?

Questions for You

  • • Do you ever feel like your muscles are 'fighting' you or feel very stiff, especially after sitting for a while?
  • • Have you noticed changes in how you process emotions or organize your thoughts, separate from the physical balance issues?
  • • Does your energy level seem to drop significantly by the end of the day, and does rest help your coordination?
  • • When you think about your symptoms, which one—balance, stiffness, or numbness—bothers you the most in your daily life?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Spastic ataxias.

    Bereznyakova O, Dupré N

    Handbook of clinical neurology 2018; (155()):191-203 doi:10.1016/B978-0-444-64189-2.00012-3.

    PMID: 29891058
  2. 2

    Functional mobility in walking adult population with ataxia of Charlevoix-Saguenay.

    Lessard I, St-Gelais R, Hébert LJ, et al.

    Orphanet journal of rare diseases 2021; (16(1)):432 doi:10.1186/s13023-021-02054-2.

    PMID: 34649570
  3. 3

    ARSACS: Clinical Features, Pathophysiology and iPS-Derived Models.

    Salem IH, Blais M, Zuluaga-Sánchez VM, et al.

    Cerebellum (London, England) 2025; (24(1)):24 doi:10.1007/s12311-024-01777-9.

    PMID: 39753868
  4. 4

    Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).

    Vogel AP, Rommel N, Oettinger A, et al.

    Journal of neurology 2018; (265(9)):2060-2070 doi:10.1007/s00415-018-8950-4.

    PMID: 29968200
  5. 5

    Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) in a Thai Patient: The Classic Clinical Manifestations, Funduscopic Feature, and Brain Imaging Findings with a Novel Mutation in the SACS Gene.

    Srikajon J, Pitakpatapee Y, Limwongse C, et al.

    Tremor and other hyperkinetic movements (New York, N.Y.) 2020; (10()):1 doi:10.5334/tohm.68.

    PMID: 32775015
  6. 6

    From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Gagnon C, Brais B, Lessard I, et al.

    Orphanet journal of rare diseases 2018; (13(1)):165 doi:10.1186/s13023-018-0898-z.

    PMID: 30231904
  7. 7

    Teaching NeuroImages: Autosomal recessive spastic ataxia of Charlevoix-Saguenay: Typical MRI findings.

    Biswas A, Varman M, Yoganathan S, et al.

    Neurology 2018; (90(14)):e1271-e1272 doi:10.1212/WNL.0000000000005252.

    PMID: 29610238
  8. 8

    Neuropathy in ARSACS is demyelinating but without typical nerve enlargement in nerve ultrasound.

    Kneer K, Straub S, Wittlinger J, et al.

    Journal of neurology 2024; (271(5)):2494-2502 doi:10.1007/s00415-023-12159-2.

    PMID: 38261029
  9. 9

    Assessment of Sacsin Turnover in Patients With ARSACS: Implications for Molecular Diagnosis and Pathogenesis.

    Longo F, De Ritis D, Miluzio A, et al.

    Neurology 2021; (97(23)):e2315-e2327 doi:10.1212/WNL.0000000000012962.

    PMID: 34649874
  10. 10

    Reduction of sacsin levels in peripheral blood mononuclear cells as a diagnostic tool for spastic ataxia of Charlevoix-Saguenay.

    De Ritis D, Ferrè L, De Winter J, et al.

    Brain communications 2024; (6(4)):fcae243 doi:10.1093/braincomms/fcae243.

    PMID: 39091421
  11. 11

    [Research advance on the pathogenesis of autosomal recessive spastic ataxia of Charlevoix-Saguenay].

    Fu R, Ding M, Lu Z

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2023; (40(1)):121-124 doi:10.3760/cma.j.cn511374-20211206-00967.

    PMID: 36585015
  12. 12

    Genetics of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Role of Sacsin in Neurodegeneration.

    Bagaria J, Bagyinszky E, An SSA

    International journal of molecular sciences 2022; (23(1)) doi:10.3390/ijms23010552.

    PMID: 35008978
  13. 13

    Molecular Characterization of Portuguese Patients with Hereditary Cerebellar Ataxia.

    Santos M, Damásio J, Carmona S, et al.

    Cells 2022; (11(6)) doi:10.3390/cells11060981.

    PMID: 35326432
  14. 14

    Whole-exome sequencing confirms implication of VPS13D as a potential cause of progressive spastic ataxia.

    Durand CM, Angelini C, Michaud V, et al.

    BMC neurology 2022; (22(1)):53 doi:10.1186/s12883-022-02553-0.

    PMID: 35151251
  15. 15

    A mitochondrial-targeted antioxidant (MitoQ) improves motor coordination and reduces Purkinje cell death in a mouse model of ARSACS.

    Márquez BT, Leung TCS, Hui J, et al.

    Neurobiology of disease 2023; (183()):106157 doi:10.1016/j.nbd.2023.106157.

    PMID: 37209925
  16. 16

    Purkinje Cells Directly Inhibit Granule Cells in Specialized Regions of the Cerebellar Cortex.

    Guo C, Witter L, Rudolph S, et al.

    Neuron 2016; (91(6)):1330-1341 doi:10.1016/j.neuron.2016.08.011.

    PMID: 27593180
  17. 17

    The Cerebellar Cognitive-Affective Syndrome Scale Reveals Consistent, Early, and Progressive Neuropsychological Deficits in Autosomal-Recessive Spastic Ataxia of Charlevoix-Saguenay: A Large International Cross-Sectional Study.

    Fortin J, Synofzik M, Pedneault-Tremblay ÉA, et al.

    Movement disorders : official journal of the Movement Disorder Society 2026; doi:10.1002/mds.70201.

    PMID: 41669957
  18. 18

    Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) - A Polish family with novel SACS mutations.

    Krygier M, Konkel A, Schinwelski M, et al.

    Neurologia i neurochirurgia polska 2017; (51(6)):481-485 doi:10.1016/j.pjnns.2017.08.003.

    PMID: 28843771
  19. 19

    SACS variants are a relevant cause of autosomal recessive hereditary motor and sensory neuropathy.

    Vill K, Müller-Felber W, Gläser D, et al.

    Human genetics 2018; (137(11-12)):911-919 doi:10.1007/s00439-018-1952-6.

    PMID: 30460542
  20. 20

    Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay without Spasticity.

    Aida I, Ozawa T, Fujinaka H, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(24)):3963-3967 doi:10.2169/internalmedicine.7401-21.

    PMID: 34121011
  21. 21

    Case Report: Expanding the Genetic and Phenotypic Spectrum of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Habibzadeh P, Tabatabaei Z, Inaloo S, et al.

    Frontiers in genetics 2020; (11()):585136 doi:10.3389/fgene.2020.585136.

    PMID: 33414805

This page provides educational information about the biology and symptoms of ARSACS. It is not intended as medical advice; always consult your neurologist or genetic counselor for guidance on your specific symptoms and care plan.

Stay up to date

Get notified when new research about Autosomal recessive spastic ataxia of Charlevoix-Saguenay is published.

No spam. Unsubscribe anytime.